8-K: Chemed Q3 Earnings Decline Amid Margin Pressures

Chemed Corporation reported a 3.1% revenue increase to $624.9 million for Q3 2025, but GAAP diluted EPS fell 10.8% to $4.46, driven by margin declines in both VITAS Healthcare and Roto-Rooter segments.

Summary

• Consolidated revenue increased 3.1% to $624.9 million for the third quarter ended September 30, 2025.
• GAAP Diluted Earnings-per-Share (EPS) decreased 10.8% to $4.46, while Adjusted Diluted EPS decreased 6.6% to $5.27.
• VITAS Healthcare segment net patient revenue rose 4.2% to $407.7 million, supported by a 2.5% increase in Average Daily Census (ADC) to 22,327 and a 5.6% increase in admissions to 17,714.
• VITAS Adjusted EBITDA, excluding Medicare Cap, declined 3.8% to $70.4 million, with its Adjusted EBITDA margin decreasing by 157-basis points to 17.0%.
• Roto-Rooter segment revenue increased 1.1% to $217.2 million.
• Roto-Rooter Adjusted EBITDA decreased 12.4% to $49.4 million, and its Adjusted EBITDA margin declined by 351-basis points to 22.7%.
• VITAS accrued $6.1 million in Medicare Cap billing limitation in Q3 2025, compared to $2.2 million in Q3 2024, with $4.6 million related to the Florida combined program.
• The company repurchased 407,500 shares of Chemed stock for $180.8 million at an average cost of $443.62 per share during the quarter.
• Management reiterated its previously issued guidance for 2025 Adjusted Diluted EPS of $22.00 to $22.30 per share, assuming no Medicare Cap related to the Florida combined program for government fiscal year 2026.

Sentiment

Score: 4

Explanation: While revenue growth is positive, significant declines in GAAP and Adjusted EPS, Net Income, and Adjusted EBITDA margins across both VITAS and Roto-Rooter segments are concerning. The increasing impact of Medicare Cap limitations on VITAS further adds to operational headwinds, indicating a challenging quarter despite top-line growth.

Positives

• Consolidated revenue increased 3.1% to $624.9 million.
• VITAS Healthcare segment reported a 4.2% increase in net patient revenue to $407.7 million.
• VITAS Average Daily Census (ADC) grew 2.5% to 22,327, and admissions increased 5.6% to 17,714.
• Roto-Rooter segment revenue increased 1.1% to $217.2 million, with strong residential plumbing (+8.2%), excavation (+4.5%), and water restoration (+6.8%) growth.
• The company maintains a strong balance sheet with $129.8 million in cash and cash equivalents and no current or long-term debt.
• Chemed has significant liquidity with $404.5 million in undrawn borrowing capacity under its credit agreement.
• The company actively returned capital to shareholders by repurchasing 407,500 shares for $180.8 million during the quarter, with $301.8 million remaining in authorization.

Negatives

• Consolidated GAAP Diluted EPS decreased 10.8% to $4.46.
• Consolidated Adjusted Diluted EPS decreased 6.6% to $5.27.
• VITAS Net Income, excluding certain discrete items, decreased 9.0% to $48.9 million.
• VITAS Adjusted EBITDA, excluding Medicare Cap, declined 3.8% to $70.4 million, and its margin decreased by 157-basis points to 17.0%.
• Roto-Rooter Net Income, excluding certain discrete items, decreased 14.8% to $33.9 million.
• Roto-Rooter Adjusted EBITDA declined 12.4% to $49.4 million, with its margin decreasing by 351-basis points to 22.7%.
• VITAS accrued $6.1 million in Medicare Cap billing limitation in Q3 2025, a significant increase from $2.2 million in Q3 2024, with five provider numbers having a total Medicare Cap billing limitation of $27.2 million.
• Acuity mix shift negatively impacted VITAS revenue growth by 121-basis points, and Medicare Cap/other contra revenue changes further impacted it by 124-basis points.
• Roto-Rooter's revenue from independent contractors declined 4.7% to $16.9 million.

Risks

• Impact of laws and regulations on operations, including Medicare Cap and Medicare reimbursement rates.
• Estimates of the effect of Medicare Cap on VITAS revenues and future prospects.
• Expectations regarding VITAS patient mix.
• Expectations regarding demand for Roto-Rooter's services.

Future Outlook

Management reiterates its previously issued guidance for 2025 Adjusted Diluted EPS of $22.00 to $22.30 per share. This guidance assumes no Medicare Cap related to the Florida combined program for the government fiscal year 2026, which begins on October 1, 2025.

Management Comments

• Management reiterates its previously issued guidance of $22.00 to $22.30 per share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items.

Industry Context

Chemed operates in two distinct service industries: end-of-life care through VITAS Healthcare and commercial/residential plumbing and drain cleaning through Roto-Rooter. The hospice segment (VITAS) faces ongoing regulatory challenges, particularly with Medicare Cap limitations and acuity mix shifts impacting revenue growth and profitability. The Roto-Rooter segment, while showing overall revenue growth, experienced mixed performance across its service lines and a decline in profitability, reflecting potential market or operational pressures within the home services sector.

Stakeholder Impact

• Shareholders are impacted by the decline in GAAP and Adjusted EPS, potentially affecting stock valuation.
• Employees and customers may be indirectly affected if operational challenges persist, though no direct impact is detailed.

Next Steps

• Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, October 29, 2025, to discuss the company's quarterly results and provide a business update.

Key Dates

Recommendation

While Chemed demonstrated revenue growth and maintains a strong balance sheet with no debt and significant share repurchase capacity, the notable declines in GAAP and Adjusted EPS, Net Income, and Adjusted EBITDA margins across both its VITAS and Roto-Rooter segments are concerning. The increasing impact of Medicare Cap limitations on VITAS further adds to operational headwinds. The reiteration of full-year guidance provides some stability, but the underlying operational performance suggests challenges in maintaining profitability, warranting a cautious 'hold' stance for investors to monitor future quarters for signs of margin recovery.

Keywords

Chemed, VITAS Healthcare, Roto-Rooter, Hospice Care, Plumbing Services, Drain Cleaning, Q3 Earnings, Financial Results, Medicare Cap, EPS, EBITDA, Revenue